Combined with the role of SPTBN2 in the TME, we reasonably speculate that SPTBN2 may be a potential predictive biomarker of immunotherapy response in patients with malignant tumors such as PAAD. Here, SPTBN2 is linked to pancreatic adenocarcinoma.